BioCentury
ARTICLE | Strategy

Lilly goes with the flow

Lilly joins the continuous manufacturing bandwagon with a CGMP process.

June 29, 2017 10:53 PM UTC

In line with FDA’s push for companies to shift from batch processing to continuous manufacturing, Eli Lilly and Co. has published details of the first CGMP process for an API. The system shrinks a multi-room footprint to equipment that fits in a fume-hood, supporting flexible, small volume production of clinical compounds.

The company believes the approach has far-reaching applications, from expanding possibilities in research to supporting programs for rare diseases and fueling the rise of personalized medicine...